Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11998618-B2

Patent

Publication Date

2024-06-04

Expiration Date


Abstract

The invention provides polynucleotides, vectors and viruses expressing frataxin and methods of treating Friedreich's Ataxia.

Core Innovation

The disclosed invention links chiral diacylhydrazine ligand structures to an ecdysone-based gene switch system for externally regulating frataxin expression. The ligand structures are defined by Formula II and Formula III, with Formula II predominantly S stereochemistry and Formula III predominantly R stereochemistry, and in at least one embodiment the enantiomeric excess is at least 95%.

In the described gene-switch context, an ecdysone-based gene switch system is used with a nucleic acid encoding human frataxin. The ligand and gene-switch combination is provided in the setting of administering an adeno-associated viral (AAV) vector to a subject.

The document further describes treating Friedreich’s Ataxia by administering an AAV vector encoding human frataxin operably linked to selected 5′UTR and 3′UTR/control elements. The nucleic acid constructs include 5′UTR selected from 5U2, FTH1, GAPDH, and RPL6-5′Splice and 3′UTR selected from SV40 early adenylation, SV40 late adenylation, human growth hormone polyadenylation (hGHpA), or a synthetic 3′ regulatory element having a nucleic acid sequence of SEQ ID NO:7.

Claims Coverage

The independent claims cover two method categories: treating Friedreich’s Ataxia symptoms by CNS-directed administration of a specified AAV vector construct, and increasing frataxin levels in a frataxin-deficient subject to at least a specified functional threshold, using essentially the same AAV construct and administration modalities. Across these independent claims, the inventive focus includes specific 5′UTR and 3′UTR/control element selections and limiting the delivery route to intrathecal, intracerebroventricular, intraparenchymal, and intracerebellar administration.

AAV vector encoding human frataxin with selected 5′UTR, selected 3′UTR, and a control element for transcription and/or translation

An AAV vector comprising a nucleic acid molecule encoding human frataxin operably linked to a 5′UTR selected from 5U2, FTH1, GAPDH, and RPL6-5′Splice; a 3′UTR selected from a SV40 early adenylation sequence, a SV40 late adenylation sequence, a human growth hormone polyadenylation sequence (hGHpA), and a synthetic 3′ regulatory element having a nucleic acid sequence of SEQ ID NO:7; and a control element that directs transcription and/or translation.

CNS-directed administration route and Friedreich’s Ataxia symptom target

Administering intrathecal (IT), intracerebroventricular (ICV), intraparenchymal, intracerebellar administration, or a combination thereof for treating at least one symptom of Friedreich's Ataxia comprising loss of coordination in the arms and/or legs.

Frataxin deficiency level threshold for increased frataxin production

Producing the frataxin encoded by the nucleic acid molecule at a level that is at least 25% of frataxin levels produced by a subject not having a frataxin deficiency.

Pharmaceutical formulation with PBS or DPBS for symptom treatment via specified UTR pairing

Administering a pharmaceutical formulation comprising an AAV vector where the 5′UTR/3′UTR pairings are specified as (i) FTH1 with SV40 early or SV40 late polyadenylation sequence, (ii) GAPDH with SV40 late polyadenylation sequence or a synthetic 3′ regulatory element having a nucleic acid sequence of SEQ ID NO:7, (iii) 5U2 with hGHpA or SEQ ID NO:7, or (iv) RPL6-5′Splice with a synthetic 3′ regulatory element having a nucleic acid sequence of SEQ ID NO:7, together with phosphate buffer solution (PBS) or Dulbecco's phosphate buffer solution (DPBS).

Across the independent claims, the coverage is grounded in an AAV vector encoding human frataxin with operable linkage to selected 5′UTR and 3′UTR/control elements, and it limits administration to intrathecal, intracerebroventricular, intraparenchymal, and intracerebellar routes. The independent claims further specify either a symptom-targeted treatment context for Friedreich’s Ataxia or an explicit functional threshold for frataxin levels of at least 25% of non-deficient levels.

Stated Advantages

Increases frataxin levels in a subject having a frataxin deficiency to at least 25% of frataxin levels produced by a subject not having a frataxin deficiency.

Treats at least one symptom of Friedreich's Ataxia, including loss of coordination in the arms and/or legs.

Provides a frataxin level sufficient to treat at least one Friedreich's Ataxia symptom in the subject.

Documented Applications

Treatment of Friedreich's Ataxia symptoms in a subject in need thereof, specifically including loss of coordination in the arms and/or legs, using IT/ICV/intraparenchymal/intracerebellar administration routes.

Increasing frataxin levels in a subject having a frataxin deficiency by administering an AAV vector encoding human frataxin configured with selected 5′UTR and 3′UTR regulatory elements.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.